Evolution of resistance during first-line treatment with boosted fosamprenavir is associated with baseline mutations. [electronic resource]
Producer: 20060629Description: 138-40 p. digitalISSN:- 0269-9370
- Adult
- Antiretroviral Therapy, Highly Active -- methods
- Carbamates -- therapeutic use
- Drug Resistance, Viral -- genetics
- Drug Therapy, Combination
- Furans
- Genotype
- HIV Infections -- drug therapy
- HIV Protease Inhibitors -- therapeutic use
- Humans
- Male
- Mutation
- Organophosphates -- therapeutic use
- Prodrugs -- therapeutic use
- Sulfonamides -- therapeutic use
No physical items for this record
Publication Type: Case Reports; Letter
There are no comments on this title.
Log in to your account to post a comment.